{"filing":{"accession_number":"0001628280-26-053836","cik":"0001357874","ticker":"DTIL","company_name":"PRECISION BIOSCIENCES INC","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"dtil-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/dtil-20260806.htm"},"events":[{"id":25861,"run_id":23478,"accession_number":"0001628280-26-053836","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses quarterly financial results including cash position ($112.4 million), R\u0026D expenses ($12.4 million), G\u0026A expenses ($6.8 million), net loss ($32.7 million), and per-share loss ($(1.26)), along with a comprehensive business update on clinical trial progress for PBGENE-HBV and PBGENE-DMD programs. The disclosure is material as it provides investors with the company's financial condition and operational milestones for the period.","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26793,"accession_number":"0001628280-26-053836","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses quarterly financial results including cash position ($112.4 million), R\u0026D expenses ($12.4 million), G\u0026A expenses ($6.8 million), net loss ($32.7 million), and per-share loss ($(1.26)), along with a comprehensive business update on clinical trial progress for PBGENE-HBV and PBGENE-DMD programs. The disclosure is material as it provides investors with the company's financial condition and operational milestones for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:17.338360+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26793,"accession_number":"0001628280-26-053836","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release discloses quarterly financial results including cash position ($112.4 million), R\u0026D expenses ($12.4 million), G\u0026A expenses ($6.8 million), net loss ($32.7 million), and per-share loss ($(1.26)), along with a comprehensive business update on clinical trial progress for PBGENE-HBV and PBGENE-DMD programs. The disclosure is material as it provides investors with the company's financial condition and operational milestones for the period.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:39:17.338360+00:00","company_name":"PRECISION BIOSCIENCES INC","ticker":"DTIL","filing_date":"2026-08-06"}]}